Quantified Evaluation of Noninvasive System Delivering Microwave Energy for Unwanted Fat Reduction and Skin Tightening in Asians.

As people age, facial skin sagging and submental fat accumulation have become concerns for many, not only affecting their appearance but also negatively impacting their self-confidence. With the continuous advancement of modern medical aesthetic technology, noninvasive treatments like microwave-assisted heating technology have provided new solutions for addressing these issues.

The microwave-assisted heating technology works by precisely heating subcutaneous fat tissue with high-frequency energy, inducing fat cell apoptosis while simultaneously stimulating collagen production in the skin, thereby achieving fat reduction and skin tightening. Compared to traditional surgical methods, this technique offers the advantages of being non-invasive, having a short recovery period, and carrying lower risks.

To further investigate these effects, we plan to conduct a prospective, open-label clinical trial. The treatment will focus on enhancing the mid and lower facial area, while carefully managing the treatment time and monitoring patient comfort.

Inclusion criteria

• Men and women aged between 20 and 60.
• Subjects who are capable of understanding and comply with the study procedures, instructions, and visit schedule.
• Subjects who voluntarily decide to participate in the entire course of the trial and provide written consent in the Informed Consent Form.

Exclusion criteria

• Subjects with autoimmune diseases/received immunotherapy and subjects with diabetes mellitus.
• Subjects with a history of a hypertrophic scar.
• Pregnant or breastfeeding women.
• Subjects with untreated epilepsy or underlying porphyria.
• When there is an active disease (such as inflammation, infection or tumors) in or near the intended treatment site.
• Treatment procedure (e.g., bioresorbable fillers, laser/light therapies, botulinum toxin A injections, facial lift, facial peels, excisional facial surgery, dermal photorejuvenation, oral or maxillofacial surgery, etc.) that may interfere with the treatment area or evaluation within 6 months before screening as determined by the Principal Investigator.
• The subject who received soft tissue augmentation at the treatment site at any time before screening as determined by the Principal Investigator.
• Subjects with a scar or skin lesion at the treatment site that may interfere with the judgment of the treatment effect.
• Subjects who participated in another clinical trial within 60 days before screening or plan to participate in another investigation during this study.
• Subjects who plan to receive other wrinkle improvement treatments in the face during this trial.
• Subjects who are otherwise determined by the investigator as ineligible for this study.